June 17, 2020

Dexamethasone reduces COVID-19 deaths by one-third

By: Judy Mathias

Editor's Note

In preliminary results of this study from the University of Oxford, UK, a low-cost steroid, dexamethasone, reduced deaths by up to one third in hospitalized patients with severe respiratory complications of COVID-19.

A total of 2,104 patients were randomized to receive dexamethasone 6 mg once per day for 10 days, and they were compared with 4,321 patients randomized to usual care alone.

Sponsored Message

In patients who received usual care alone, 28-day mortality was highest in those who required ventilation (41%), intermediate in those who required oxygen only (25%), and lowest in those who did not require any respiratory interventions (13%).

Dexamethasone reduced deaths by one-third in ventilated patients, by one-fifth in those receiving oxygen only, and there was no benefit in patients who did not require respiratory support.

These preliminary results from the RECOVERY (Randomized Evaluation of COVid-19 thERapY) trial are very clear that dexamethasone reduces the risk of death in COVID-19 patients with severe respiratory complications, the researchers say.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat